A review of dupilumab in the treatment of atopic diseases
Dupilumab is a fully human monoclonal IgG4 antibody directed against the alpha subunit of the IL-4 receptor and prevents the signaling of IL-4 and IL-13, two type 2 cytokines known to be important drivers of atopic diseases. In March of 2017, the United States Food and Drug Administration (FDA) appr...
Guardado en:
| Autores principales: | , , , , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Taylor & Francis Group
2019-09-01
|
| Colección: | Human Vaccines & Immunotherapeutics |
| Materias: | |
| Acceso en línea: | http://dx.doi.org/10.1080/21645515.2019.1582403 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|